CY1113554T1 - Πεδια και επιτοποι μηνιγγοκοκκικης πρωτεϊνης νμβ1870 - Google Patents

Πεδια και επιτοποι μηνιγγοκοκκικης πρωτεϊνης νμβ1870

Info

Publication number
CY1113554T1
CY1113554T1 CY20131100064T CY131100064T CY1113554T1 CY 1113554 T1 CY1113554 T1 CY 1113554T1 CY 20131100064 T CY20131100064 T CY 20131100064T CY 131100064 T CY131100064 T CY 131100064T CY 1113554 T1 CY1113554 T1 CY 1113554T1
Authority
CY
Cyprus
Prior art keywords
nmb1870
family
families
domains
trans
Prior art date
Application number
CY20131100064T
Other languages
English (en)
Inventor
Vega Masignani
Maria Scarselli
Rino Rappuoli
Mariagrazia Pizza
Marzia Giuliani
Marcello Federica Di
Daniele Veggi
Laura Ciucchi
Original Assignee
Novartis Vaccines And Diagnostics S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics S.R.L. filed Critical Novartis Vaccines And Diagnostics S.R.L.
Publication of CY1113554T1 publication Critical patent/CY1113554T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

«ΝΜΒ1870» είναι μια γνωστή πρωτεΐνη επιφανείας σε Neisseria meningitidis εκφρασμένη σε όλες τις οροομάδες. Έχει τρεις διακριτές οικογένειες. Ορός εγειρόμενος έναντι μιας δοθείσας οικογένειας είναι βακτηριοκτόνος εντός της ίδιας οικογένειας, αλλά δεν είναι δραστικός έναντι στελεχών, τα οποία εκφράζουν μία από τις άλλες δύο οικογένειες, δηλαδή ενδο-οικογένειας αλλά όχι δια-οικογένειας εγκάρσια-προστασία. Οι εφευρέτες έχουν βρει ότι η ΝΜΒ1870 μπορεί να διαιρείται σε πεδία και ότι δεν απαιτούνται όλα τα πεδία για αντιγονικότητα. Αντιγονικά πεδία μπορεί να ληφθούν από καθεμία από τις τρεις ΝΜΒ1870 οικογένειες και εκφράζονται ως απλού πολυπεπτιδίου άλυσος. Οι εφευρέτες έχουν επίσης βρει ότι η ΝΜΒ1870 εκθέτει μερικούς από τους επίτοπους αυτής σε βρόχους επιφανείας τοποθετημένους μεταξύ άλφα ελίκων και ότι υποκατάσταση επίτοπων βρόχου από μία οικογένεια εντός της τοποθεσίας βρόχου σε άλλη οικογένεια επιτρέπει να παράγεται χιμαιρική ΝΜΒ1870 με πολυ-οικογένειας αντιγονικότητα. Παρέχονται αυτές οι χιμαιρικές ΝΜΒ1870 πρωτεΐνες, που περιλαμβάνουν τμήματα της ΝΜΒ1870 από διαφορετικές οικογένειες.
CY20131100064T 2004-09-01 2013-01-23 Πεδια και επιτοποι μηνιγγοκοκκικης πρωτεϊνης νμβ1870 CY1113554T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0419408A GB0419408D0 (en) 2004-09-01 2004-09-01 741 chimeric polypeptides
EP20050786178 EP1784419B1 (en) 2004-09-01 2005-09-01 Domains and epitopes of meningococcal protein nmb1870

Publications (1)

Publication Number Publication Date
CY1113554T1 true CY1113554T1 (el) 2016-06-22

Family

ID=33155851

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100064T CY1113554T1 (el) 2004-09-01 2013-01-23 Πεδια και επιτοποι μηνιγγοκοκκικης πρωτεϊνης νμβ1870

Country Status (20)

Country Link
US (1) US20090285845A1 (el)
EP (1) EP1784419B1 (el)
JP (2) JP4827196B2 (el)
CN (1) CN101031584B (el)
AU (1) AU2005278904B2 (el)
BR (1) BRPI0514829A (el)
CA (1) CA2578014A1 (el)
CY (1) CY1113554T1 (el)
DK (1) DK1784419T3 (el)
ES (1) ES2396422T3 (el)
GB (1) GB0419408D0 (el)
HR (1) HRP20130036T1 (el)
MX (1) MX2007002094A (el)
NZ (1) NZ553229A (el)
PL (1) PL1784419T3 (el)
PT (1) PT1784419E (el)
RS (1) RS52634B (el)
RU (1) RU2375374C2 (el)
SI (1) SI1784419T1 (el)
WO (1) WO2006024954A2 (el)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2304065T3 (es) 1998-05-01 2008-09-01 Novartis Vaccines And Diagnostics, Inc. Antigenos y composiciones de neisseria meningitidis.
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
AU783894B2 (en) 1999-05-19 2005-12-22 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
RU2281956C2 (ru) 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
DK2289545T3 (en) * 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
CN100473663C (zh) 2000-02-28 2009-04-01 启龙股份公司 奈瑟球菌蛋白质的异源表达
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003274511B2 (en) * 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
US9511131B2 (en) * 2008-03-10 2016-12-06 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
US20100105875A1 (en) * 2008-06-09 2010-04-29 Maria Scarselli Antibodies against neisserial factor H binding protein
JP5668049B2 (ja) * 2009-03-24 2015-02-12 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
CN102711814A (zh) * 2009-04-30 2012-10-03 奥克兰儿童医院及研究中心 一种嵌合h因子结合蛋白(fhbp)及其使用方法
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
NZ598459A (en) 2009-08-27 2014-03-28 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
EP2493499A1 (en) 2009-10-27 2012-09-05 Novartis AG Modified meningococcal fhbp polypeptides
EP3327028B1 (en) 2010-03-30 2022-03-16 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
JP2015521595A (ja) 2012-06-14 2015-07-30 ノバルティス アーゲー 血清群ｘ髄膜炎菌のためのワクチン
CN104736563A (zh) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
EA201690056A8 (ru) 2013-08-02 2017-07-31 Чилдренс Хоспитл Энд Рисерч Сентер Эт Окленд ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
SG11201606478YA (en) 2014-02-28 2016-09-29 Glaxosmithkline Biolog Sa Modified meningococcal fhbp polypeptides
KR20230012100A (ko) * 2014-07-17 2023-01-25 글락소스미스클라인 바이오로지칼즈 에스.에이. 수막구균 백신
MX2017000776A (es) 2014-07-17 2017-05-04 Glaxosmithkline Biologicals Sa Polipeptidos fhbp meningococicos modificados.
WO2016014719A1 (en) 2014-07-23 2016-01-28 Children's Hospital & Research Center Oakland Factor h binding protein variants and methods of use thereof
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
EP3298031B1 (en) 2015-05-18 2020-10-21 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
EP3536706A1 (en) 2018-03-09 2019-09-11 BiOMVis Srl Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof
EP3725371A1 (en) 2019-04-18 2020-10-21 BiOMVis Srl Method for the production of outer membrane vesicles and immunogenic compositions thereof
US20240016916A1 (en) 2020-05-15 2024-01-18 Biomvis S.R.L. Bacterial outer membrane vesicles carrying coronavirus polypeptides, method of preparation, compositions and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2304065T3 (es) 1998-05-01 2008-09-01 Novartis Vaccines And Diagnostics, Inc. Antigenos y composiciones de neisseria meningitidis.
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
AU783894B2 (en) * 1999-05-19 2005-12-22 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
DK2289545T3 (en) * 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
CN100473663C (zh) * 2000-02-28 2009-04-01 启龙股份公司 奈瑟球菌蛋白质的异源表达
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
JP2006500963A (ja) * 2002-08-02 2006-01-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
AU2003274511B2 (en) * 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
WO2004067030A2 (en) * 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CA2756522C (en) * 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein

Also Published As

Publication number Publication date
AU2005278904A1 (en) 2006-03-09
ES2396422T3 (es) 2013-02-21
DK1784419T3 (da) 2013-02-04
SI1784419T1 (sl) 2013-02-28
PT1784419E (pt) 2013-01-15
JP4827196B2 (ja) 2011-11-30
CA2578014A1 (en) 2006-03-09
EP1784419A2 (en) 2007-05-16
GB0419408D0 (en) 2004-10-06
PL1784419T3 (pl) 2013-03-29
HRP20130036T1 (hr) 2013-02-28
WO2006024954A9 (en) 2012-03-15
WO2006024954A3 (en) 2006-08-24
AU2005278904B2 (en) 2012-02-09
CN101031584B (zh) 2012-09-05
RS52634B (en) 2013-06-28
MX2007002094A (es) 2007-04-24
CN101031584A (zh) 2007-09-05
RU2375374C2 (ru) 2009-12-10
JP2011168611A (ja) 2011-09-01
US20090285845A1 (en) 2009-11-19
JP2008511306A (ja) 2008-04-17
EP1784419B1 (en) 2012-10-24
NZ553229A (en) 2010-07-30
RU2007111700A (ru) 2008-10-10
WO2006024954A2 (en) 2006-03-09
BRPI0514829A (pt) 2008-06-24

Similar Documents

Publication Publication Date Title
CY1113554T1 (el) Πεδια και επιτοποι μηνιγγοκοκκικης πρωτεϊνης νμβ1870
CY1112342T1 (el) Χιμαιρικα, υβριδικα και διαδοχικα πολυπεπτιδια μηνιγγοκοκκικου νμβ1870
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
EA201301072A1 (ru) Антитела против il-23p19 и их применение
CY1119019T1 (el) Πολλαπλες παραλλαγες μηνιγγιοκοκκικης πρωτεϊνης νμβ 1870
NO20063026L (no) Antistoffer
NO2016007I1 (no) Susoktokog
RS54046B1 (en) ANTI-MIOSTATIN ANTITELA
CY1109649T1 (el) Αντιγονα και συνθεσεις απο neisseria
RS53215B (en) NEUTRAL ANTIBODIES HAVING SPECIFICITY TO HUMAN IL-17
RS54468B1 (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
BRPI0417823A (pt) métodos para uso de bifidobactérias probióticas para animais de estimação
CO5700152A1 (es) Nuevos anticuerpos anti-igf-ir y sus usos
BR0108711A (pt) Expressão heteróloga de proteìnas de neisseria
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
DK1244705T3 (da) Serpentintransmembrane antigener udtryk i human prostatacancere og anvendelser deraf
ATE432986T1 (de) Menschlicher rezeptor für tumor necrosis factor
IL172396A0 (en) Replikin peptides and uses thereof
PE20040562A1 (es) Vacunas que comprenden mezclas de cepas meningococicas multivalentes
BRPI0418317A (pt) vacina de aumento de crescimento à base de epitopo de neutralização
GEP20105022B (en) Use of polypeptides of the cupredoxin family in cancer therapy
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
DK2040560T3 (da) Cysteingranuler og anvendelse deraf som bifidobacterium animalis lactis vækststimulanter
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper